Tajikistan Medical Device Quality Standards: Pharmacopoeia and Technical Regulations

1. Key takeaways

The quality standards system of Tajikistan consists of four categories of documents: the national pharmacopoeia and other recognized pharmacopoeias, general pharmacopoeia monographs, technical regulations, technical conditions, as well as other documents indicated by manufacturers or the relevant state bodies. Article 16(1) of Law No. 1893 enumerates this system; Article 16(7) further provides that the quality requirements for medical products and quasi-medicinal products apply according to the quality specification documents, technical conditions and other standards on the basis of which they passed state registration. GRZAN notes that Article 16(7) is the core provision of the entire quality compliance system: it anchors the determination of quality requirements to the documents relied upon at registration, which means the quality documents in the registration dossier carry long-term binding force.

2. Legal basis

3. Expert insights

Insight 1: Article 16(7) is the core provision for device companies, yet it is often overlooked. The provision states that the quality requirements for medical products and quasi-medicinal products apply according to the quality specification documents, technical conditions and other standards on the basis of which they passed state registration. The key lies in that qualifier. Its legal effect is that the quality documents submitted in the registration dossier become the quality determination benchmark for the product thereafter in Tajikistan, including for the batch-by-batch conformity assessment under Article 13(1). GRZAN reviews quality documents against the standard that this document will govern every batch shipped over the coming five years.

Insight 2: Article 16(1) brings documents indicated by the manufacturer into the standards system, which is highly favorable for device companies. After enumerating the national pharmacopoeia, pharmacopoeia monographs, technical regulations and technical conditions, the provision adds other documents indicated by manufacturers or the relevant state bodies. The implication is that the manufacturer’s own technical specification documents form part of the standards system. This echoes Article 33(2), under which technical testing examines the product against the intended use defined in the manufacturer’s documents, and together they establish the quasi-normative status of manufacturer documents in Tajikistan.

Insight 3: The general pharmacopoeia monographs of Article 16(3) target medicines and pharmaceutical substances and do not directly apply to devices. The three categories listed, covering the quality of medicines and pharmaceutical substances, reagents and reference standards with methods, and packaging and production materials, all point to medicines. This again confirms the central judgment of this series: Law No. 1893 is a medicines-centered law that brings medical products within its scope. When researching quality requirements, device companies should go directly to Article 16(7).

Insight 4: Article 16(5) makes compliance with quality specification documents a mandatory obligation. The provision states that persons engaged in pharmaceutical activities and circulation must comply with the national pharmacopoeia, pharmacopoeia monographs and other quality specification documents. Combined with Article 9(7), on inspections of good pharmaceutical practice compliance, the structure that emerges is: quality specification documents are both the determination benchmark and the inspection basis. In principle, every business activity of a company in Tajikistan takes place under the constraint of these documents.

Insight 5: Article 8(17) and Article 16(1) together form the entry point for foreign standards. Article 16(1) recognizes other pharmacopoeias recognized by Tajikistan, and Article 8(17) authorizes the Ministry of Health to recognize, where necessary, the pharmacopoeias and quality standards of other countries for medicines and medical products. Read together, the two provisions provide the institutional channel through which Chinese and international standards may enter the Tajik determination system, but recognition by the Ministry of Health is required on a case-by-case basis; the standards do not apply automatically.

4. Practical recommendations

1. Review quality documents against the long-term constraint standard. Under Article 16(7), the quality specification documents and technical conditions in the dossier will become the determination benchmark for every batch over five years. GRZAN recommends a joint review by technical, quality and regulatory functions before submission, focusing on the testability of each specification and internal consistency.
2. Make good use of the manufacturer document channel of Article 16(1). In the list of applicable standards, expressly include the manufacturer’s technical specification documents and explain their hierarchy relative to technical regulations and technical conditions, so as to avoid a gap in the applicability of standards.
3. Cite Article 16(7) directly, not the general pharmacopoeia monographs. Under Article 16(3), the general monographs target medicines. When compiling the quality volume, device companies should rely on paragraph 7 as the direct basis and avoid citing inapplicable provisions by mistake.
4. Prepare a recognition application for foreign standards. Under Article 8(17), where Chinese or international standards are to be cited, prepare a separate recognition application with comparison materials demonstrating equivalence to Tajik requirements.
5. Establish a change management process for quality specification documents. Under Article 16(6), amendments to the pharmacopoeia and monographs are determined by the Ministry of Health upon submission by the supervisory authority. Establish a tracking mechanism for Tajik standard updates and assess the impact on the product whenever changes occur.

5. Verification checklist

• □ Article 16(7) has been confirmed as the direct basis for the quality requirements of medical products
• □ The joint three-function review of quality documents has been completed against the standard of long-term constraint on every batch
• □ Manufacturer technical specification documents have been included in the list of applicable standards (Article 16(1))
• □ It has been confirmed that the general pharmacopoeia monographs of Article 16(3) were not cited by mistake (that paragraph targets medicines)
• □ A recognition application and comparison materials for the foreign standards to be cited have been prepared (Article 8(17))
• □ A tracking mechanism for Tajik pharmacopoeia and monograph updates has been established (Article 16(6))
• □ The mandatory compliance obligation of Article 16(5) has been incorporated into the quality system

Regulatory information verified as of October 29, 2026.

In the Central Asian market, GRZAN focuses its core capabilities on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a national track and a Union track coexist; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries, undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system compliant with ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com